Language
Eagle Pharmaceuticals Terminates License Agreement After FDA Rejects AOP Orphan's Heart Drug Application

News

HomeHome / News / Eagle Pharmaceuticals Terminates License Agreement After FDA Rejects AOP Orphan's Heart Drug Application
search
RECENT NEWS

Jun 21, 2023

Odyssey Marine Exploration Announces Partnership with Ocean Minerals LLC for a New Cook Islands Exploration Project

Aug 01, 2023

Analysis of the impact of DGAT1 p.M435L and p.K232A variants on pre

Sep 06, 2023

Could ultra

Oct 10, 2023

Sunrise Group among the world's top ten chemical distributors

Oct 14, 2023

Orally Disintegrating Tablet Excipient Market Research Report 2023

SEND YOUR INQUIRY
SUBMIT

Sep 29, 2023

Eagle Pharmaceuticals Terminates License Agreement After FDA Rejects AOP Orphan's Heart Drug Application

By Denny Jacob Eagle Pharmaceuticals said Friday it terminated a license

By Denny Jacob

Eagle Pharmaceuticals said Friday it terminated a license agreement with AOP Orphan Pharmaceuticals after the Food and Drug Administration refused to approve AOP's new drug application for heart-rate drug landiolol.

The biotechnology pharmaceutical company said AOP granted it an exclusive royalty-bearing license under certain patent rights, among other terms, under the prior license agreement. Eagle Pharmaceuticals delivered the notice terminating the agreement on Tuesday, according to a regulatory filing. The company said it can't be certain that AOP won't dispute the company's notice or on what terms any potential dispute may be resolved.

Landiolol is an intravenous candidate aimed at reducing the ventricular rate in patients with supraventricular tachycardia in the short term.

Write to Denny Jacob at [email protected]

It's been an eventful week for crypto. Earlier this week, The U.S. Securities and Exchange Commission cracked down on crypto with two lawsuits filed against two large and popular exchanges in the United States, Binance and Coinbase COIN.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More.